European Commission greenlights $16.5B Novo-Catalent acquisition
Despite months of biopharma industry pushback, the European Commission has unconditionally approved Novo Holdings’ $16.5 billion acquisition of Catalent. The Federal Trade Commission’s decision is...
View ArticleInsurance executive killing puts spotlight on security measures at JP Morgan...
The usual enhanced security measures are expected to be in place in San Francisco next month when the healthcare industry descends on the city for the JP Morgan healthcare conference. But it's not yet...
View ArticleBioAge Labs scraps Phase 2 obesity trial just months after IPO
BioAge Labs is scrapping a Phase 2 trial testing its anti-obesity drug, a few months after its flashy $198 million initial public offering. After a brief trading halt, the biotech’s shares ...
View ArticleLilly beats Novo in weight loss; Apogee plots Dupixent challenge; Biosecure...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleBiosecure bill is left out of end-of-year defense package
Legislation targeting popular Chinese biotech contractors like WuXi AppTec wasn't included in must-pass defense legislation that represented its best chances as this session of Congress draws to a...
View Article#ASH24: AstraZeneca outlines Phase 1 data for CD19 bispecific T cell engager...
SAN DIEGO — AstraZeneca is getting ready to step on the gas in the world of bispecific T cell engagers. The company presented some of its first Phase 1 data for its CD3xCD19 bispecific known ...
View Article#ASH24: Beam shares results from seven patients who received gene-edited...
SAN DIEGO — Beam Therapeutics now has trial data from seven patients who have received its gene-edited sickle cell therapy, showing promising early signs that the therapy could be used to treat severe...
View ArticleDutch biotech Citryll nabs €85M to position inflammatory antibody for a...
Citryll, a Dutch biotech that has largely flown under the radar for most of its nearly 10-year history, has patched together an €85 million Series B to test a monoclonal antibody in two inflammatory...
View ArticleADC scientist who paved the way for Daiichi’s Enhertu dies
The “scientific trailblazer” behind Daiichi Sankyo’s blockbuster ADC medicines, Toshinori Agatsuma, has passed away, the company said Monday. Agatsuma was head of research at the Japanese drugmaker,...
View ArticleDimension nabs $500M second fund for 'still contrary' intersection of bio and...
Dimension has crossed a key threshold. The VC firm's trio of New York and Bay Area managing partners has raised a sophomore fund in the arduous field of life sciences investing. That group — Zavain Dar...
View ArticleEnanta's mid-stage win in pediatric RSV; Carisma to lay off 34% of staff
Plus, news about Innovent Biologics, Relmada Therapeutics, Zevra Therapeutics, Incyte and Bionical Emas: Enanta’s Ph2 win in RSV: The company’s oral N-protein inhibitor achieved a 1.4 log decline in...
View ArticleAmazon Pharmacy, Ro say they help patients stick with GLP-1 drugs longer
Patients who get their GLP-1 weight loss medication prescriptions filled at Amazon Pharmacy are more likely to keep taking the medications than other published research shows, Amazon Pharmacy Vice...
View ArticleMerck's Keytruda combo misses overall survival in Phase 3 trial in ovarian...
Merck said a Keytruda regimen hit the primary endpoint of progression-free survival in a Phase 3 study that enrolled certain patients with ovarian cancer, but it failed to hit the secondary endpoint of...
View ArticleAbbVie declares third Phase 3 Parkinson’s win from Cerevel takeover
There’s a silver lining for AbbVie on its closely-followed buyout of Cerevel: The pharma company reported Monday that its Parkinson’s disease candidate notched another win. This comes after it said...
View Article#ASH24: AbbVie, Genmab tout Epkinly combinations in earlier lines of...
SAN DIEGO — AbbVie and Genmab are building the case for their bispecific Epkinly in earlier lines of treatment, presenting longer-term combination data in two types of non-Hodgkin lymphoma. At the...
View ArticleICER finds Vertex's non-opioid pain treatment could bring cost savings at a...
The cost-effectiveness watchdog ICER found that Vertex’s future non-opioid treatment for acute pain could be cost-saving, but only at a low price, according to a draft report released on Monday by the...
View Article#ASH24: GSK reports Blenrep overall survival data in multiple myeloma as it...
SAN DIEGO — Two years after pulling Blenrep from the market, GSK is positioning for a relaunch. This time, the company says it’s coming from a “fundamentally different starting point,” including new...
View ArticleVijay Pande hands a16z biotech leadership to Vineeta Agarwala
The biotech and life sciences team at a16z is getting a new leader, as founding investor Vijay Pande moves into a role focused on artificial intelligence and its healthcare applications, Endpoints News...
View ArticleAgios' stock drops after disclosing new liver-related safety warning in...
Agios Pharmaceuticals on Monday saw its stock price drop by more than 24% as it disclosed that its oral candidate for the blood disorder thalassemia has been submitted to regulators worldwide for...
View ArticleBelharra Therapeutics sticks with lead programs, trims workforce by 40%
San Diego startup Belharra Therapeutics, a biotech creating small molecule cancer and immunology medicines, has laid off 21 employees, Endpoints News has confirmed. Belharra, from the same team as...
View Article